Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 396 | 2025 | 11837 | 13.260 |
Why?
|
Stroke Volume | 296 | 2025 | 5595 | 9.960 |
Why?
|
Angiotensin Receptor Antagonists | 101 | 2024 | 1060 | 6.830 |
Why?
|
Tetrazoles | 89 | 2024 | 918 | 6.540 |
Why?
|
Biphenyl Compounds | 102 | 2024 | 1019 | 5.720 |
Why?
|
Ventricular Function, Left | 134 | 2025 | 3930 | 4.730 |
Why?
|
Spironolactone | 41 | 2024 | 415 | 3.880 |
Why?
|
Drug Combinations | 90 | 2024 | 2075 | 3.720 |
Why?
|
Ventricular Dysfunction, Left | 45 | 2024 | 2136 | 3.480 |
Why?
|
Naphthyridines | 16 | 2025 | 182 | 3.270 |
Why?
|
Glucosides | 27 | 2024 | 532 | 3.040 |
Why?
|
Influenza Vaccines | 24 | 2025 | 780 | 2.980 |
Why?
|
Natriuretic Peptide, Brain | 56 | 2024 | 1735 | 2.950 |
Why?
|
Benzhydryl Compounds | 35 | 2024 | 943 | 2.900 |
Why?
|
Enalapril | 28 | 2024 | 317 | 2.840 |
Why?
|
Neprilysin | 33 | 2024 | 484 | 2.590 |
Why?
|
Influenza, Human | 27 | 2025 | 1539 | 2.560 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 44 | 2024 | 1513 | 2.210 |
Why?
|
Hospitalization | 81 | 2024 | 10810 | 1.800 |
Why?
|
Peptide Fragments | 48 | 2024 | 5126 | 1.780 |
Why?
|
Glomerular Filtration Rate | 27 | 2025 | 2233 | 1.510 |
Why?
|
Myocardial Infarction | 36 | 2025 | 11508 | 1.460 |
Why?
|
Aged | 318 | 2025 | 171163 | 1.450 |
Why?
|
Diabetes Mellitus, Type 2 | 45 | 2024 | 12235 | 1.340 |
Why?
|
Double-Blind Method | 80 | 2025 | 12417 | 1.320 |
Why?
|
Echocardiography | 44 | 2024 | 5040 | 1.320 |
Why?
|
Cardiovascular Diseases | 58 | 2024 | 15645 | 1.280 |
Why?
|
Renal Insufficiency, Chronic | 24 | 2024 | 2307 | 1.260 |
Why?
|
Randomized Controlled Trials as Topic | 38 | 2025 | 10380 | 1.250 |
Why?
|
Atherosclerosis | 26 | 2024 | 3419 | 1.250 |
Why?
|
Humans | 569 | 2025 | 765926 | 1.230 |
Why?
|
Cardiomyopathy, Hypertrophic | 10 | 2024 | 1338 | 1.200 |
Why?
|
Blood Pressure | 30 | 2024 | 8530 | 1.130 |
Why?
|
Male | 366 | 2025 | 363815 | 1.120 |
Why?
|
Middle Aged | 275 | 2025 | 223016 | 1.100 |
Why?
|
Pulmonary Edema | 7 | 2024 | 409 | 1.070 |
Why?
|
Treatment Outcome | 133 | 2025 | 65194 | 1.060 |
Why?
|
Female | 366 | 2025 | 396141 | 1.060 |
Why?
|
Diabetes Mellitus | 22 | 2025 | 5889 | 1.040 |
Why?
|
Data Interpretation, Statistical | 9 | 2021 | 2688 | 1.040 |
Why?
|
Troponin T | 11 | 2024 | 785 | 1.010 |
Why?
|
Urea | 9 | 2024 | 449 | 1.000 |
Why?
|
Atrial Fibrillation | 22 | 2024 | 5186 | 1.000 |
Why?
|
Prognosis | 99 | 2024 | 29890 | 0.980 |
Why?
|
Ramipril | 10 | 2024 | 102 | 0.940 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 15 | 2024 | 428 | 0.930 |
Why?
|
Vaccination | 22 | 2025 | 3430 | 0.880 |
Why?
|
Heart Ventricles | 17 | 2024 | 3833 | 0.840 |
Why?
|
Heart Failure, Diastolic | 5 | 2024 | 77 | 0.830 |
Why?
|
Endpoint Determination | 6 | 2019 | 591 | 0.810 |
Why?
|
Hypertension | 23 | 2023 | 8616 | 0.780 |
Why?
|
Aged, 80 and over | 101 | 2024 | 59496 | 0.780 |
Why?
|
Hypotension | 8 | 2024 | 885 | 0.760 |
Why?
|
Atrial Function, Left | 7 | 2021 | 189 | 0.720 |
Why?
|
Troponin I | 6 | 2024 | 656 | 0.720 |
Why?
|
Prospective Studies | 95 | 2024 | 54807 | 0.710 |
Why?
|
Heart Atria | 13 | 2022 | 1363 | 0.710 |
Why?
|
Risk Factors | 107 | 2024 | 74850 | 0.700 |
Why?
|
Cause of Death | 25 | 2024 | 3715 | 0.660 |
Why?
|
Hematinics | 7 | 2023 | 282 | 0.660 |
Why?
|
Antihypertensive Agents | 13 | 2023 | 2028 | 0.650 |
Why?
|
Acute Coronary Syndrome | 10 | 2023 | 2185 | 0.640 |
Why?
|
Hyperkalemia | 8 | 2023 | 233 | 0.630 |
Why?
|
Risk Assessment | 44 | 2024 | 24275 | 0.620 |
Why?
|
Prealbumin | 7 | 2024 | 264 | 0.610 |
Why?
|
Ventricular Remodeling | 14 | 2024 | 1276 | 0.610 |
Why?
|
Heart Failure, Systolic | 4 | 2023 | 135 | 0.590 |
Why?
|
Benzimidazoles | 6 | 2020 | 862 | 0.590 |
Why?
|
Hypertrophy, Left Ventricular | 9 | 2022 | 855 | 0.590 |
Why?
|
Cardiomyopathies | 9 | 2024 | 2068 | 0.580 |
Why?
|
Proportional Hazards Models | 29 | 2024 | 12529 | 0.570 |
Why?
|
Hypoglycemic Agents | 13 | 2024 | 3106 | 0.570 |
Why?
|
Ventricular Dysfunction, Right | 5 | 2024 | 645 | 0.560 |
Why?
|
Stroke | 19 | 2023 | 9739 | 0.560 |
Why?
|
Death, Sudden, Cardiac | 7 | 2024 | 1568 | 0.560 |
Why?
|
Natriuretic Peptides | 8 | 2023 | 153 | 0.550 |
Why?
|
Kidney | 19 | 2024 | 7073 | 0.550 |
Why?
|
Life Expectancy | 3 | 2018 | 1247 | 0.530 |
Why?
|
Exercise Tolerance | 6 | 2024 | 841 | 0.530 |
Why?
|
Exercise Test | 6 | 2024 | 2185 | 0.530 |
Why?
|
Anemia | 7 | 2024 | 1514 | 0.520 |
Why?
|
Echocardiography, Doppler | 11 | 2020 | 899 | 0.500 |
Why?
|
Kidney Failure, Chronic | 9 | 2024 | 2504 | 0.490 |
Why?
|
Time Factors | 46 | 2024 | 40097 | 0.480 |
Why?
|
Quality of Life | 24 | 2024 | 13463 | 0.480 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2018 | 878 | 0.480 |
Why?
|
Amyloid Neuropathies, Familial | 3 | 2023 | 187 | 0.470 |
Why?
|
Research Design | 9 | 2023 | 6204 | 0.440 |
Why?
|
Denmark | 10 | 2025 | 774 | 0.440 |
Why?
|
Follow-Up Studies | 51 | 2024 | 39228 | 0.440 |
Why?
|
Angiotensins | 7 | 2024 | 139 | 0.440 |
Why?
|
Hypokalemia | 5 | 2019 | 152 | 0.430 |
Why?
|
Prediabetic State | 4 | 2022 | 547 | 0.420 |
Why?
|
Sex Factors | 23 | 2025 | 10611 | 0.420 |
Why?
|
Survival Rate | 27 | 2022 | 12822 | 0.410 |
Why?
|
Diastole | 11 | 2023 | 785 | 0.410 |
Why?
|
Incidence | 36 | 2024 | 21513 | 0.400 |
Why?
|
Diabetic Angiopathies | 4 | 2020 | 805 | 0.400 |
Why?
|
Diuretics | 7 | 2023 | 611 | 0.400 |
Why?
|
Polypharmacy | 3 | 2024 | 306 | 0.390 |
Why?
|
Proteomics | 6 | 2024 | 3906 | 0.380 |
Why?
|
Coronary Disease | 7 | 2023 | 5919 | 0.370 |
Why?
|
Defibrillators, Implantable | 5 | 2021 | 1497 | 0.360 |
Why?
|
Potassium | 5 | 2025 | 1312 | 0.360 |
Why?
|
Kaplan-Meier Estimate | 14 | 2024 | 6503 | 0.360 |
Why?
|
Adrenergic beta-Antagonists | 6 | 2023 | 1238 | 0.350 |
Why?
|
Longitudinal Studies | 13 | 2023 | 14745 | 0.350 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1183 | 0.340 |
Why?
|
Health Status | 9 | 2024 | 4085 | 0.340 |
Why?
|
Erythropoietin | 3 | 2023 | 716 | 0.330 |
Why?
|
Mortality | 9 | 2024 | 2910 | 0.330 |
Why?
|
Diabetic Nephropathies | 5 | 2023 | 968 | 0.330 |
Why?
|
Coronary Artery Disease | 9 | 2023 | 6544 | 0.330 |
Why?
|
Systole | 10 | 2023 | 935 | 0.330 |
Why?
|
United States | 59 | 2024 | 72909 | 0.320 |
Why?
|
Survival Analysis | 12 | 2022 | 10086 | 0.320 |
Why?
|
Benzylamines | 6 | 2024 | 251 | 0.320 |
Why?
|
Blood Glucose | 11 | 2024 | 6422 | 0.320 |
Why?
|
Heart-Assist Devices | 5 | 2022 | 1297 | 0.320 |
Why?
|
Uracil | 6 | 2024 | 210 | 0.310 |
Why?
|
Predictive Value of Tests | 22 | 2024 | 15401 | 0.300 |
Why?
|
Obesity | 14 | 2024 | 13082 | 0.300 |
Why?
|
Death, Sudden | 3 | 2022 | 301 | 0.290 |
Why?
|
Peptides | 7 | 2023 | 4331 | 0.290 |
Why?
|
Biometry | 1 | 2011 | 571 | 0.290 |
Why?
|
Thiazolidinediones | 1 | 2011 | 459 | 0.290 |
Why?
|
Amyloidosis | 3 | 2024 | 883 | 0.280 |
Why?
|
Renal Dialysis | 5 | 2023 | 1791 | 0.280 |
Why?
|
Laparoscopy | 1 | 2019 | 2037 | 0.280 |
Why?
|
Propanolamines | 2 | 2018 | 163 | 0.280 |
Why?
|
Atrial Function, Right | 2 | 2018 | 32 | 0.280 |
Why?
|
Clinical Trials as Topic | 11 | 2024 | 8037 | 0.280 |
Why?
|
Heart | 6 | 2023 | 4419 | 0.280 |
Why?
|
Neoplasms | 10 | 2023 | 22340 | 0.280 |
Why?
|
Heart Rate | 8 | 2023 | 4203 | 0.270 |
Why?
|
Cohort Studies | 31 | 2024 | 41680 | 0.270 |
Why?
|
Kidney Diseases | 4 | 2023 | 2100 | 0.270 |
Why?
|
Europe | 11 | 2023 | 3430 | 0.270 |
Why?
|
Recurrence | 8 | 2024 | 8492 | 0.250 |
Why?
|
Gastrointestinal Agents | 2 | 2021 | 511 | 0.250 |
Why?
|
Sex Characteristics | 5 | 2023 | 2645 | 0.250 |
Why?
|
Smoking | 8 | 2021 | 9082 | 0.250 |
Why?
|
Thrombolytic Therapy | 2 | 2023 | 2050 | 0.250 |
Why?
|
Furosemide | 3 | 2023 | 174 | 0.250 |
Why?
|
Immunotherapy | 2 | 2018 | 4746 | 0.250 |
Why?
|
Sample Size | 5 | 2017 | 843 | 0.250 |
Why?
|
Crohn Disease | 4 | 2021 | 2281 | 0.250 |
Why?
|
Intestinal Mucosa | 5 | 2020 | 3048 | 0.250 |
Why?
|
Cardiovascular Agents | 2 | 2024 | 848 | 0.240 |
Why?
|
Ventricular Function, Right | 3 | 2024 | 629 | 0.240 |
Why?
|
Correspondence as Topic | 1 | 2024 | 34 | 0.230 |
Why?
|
Albuminuria | 5 | 2023 | 659 | 0.230 |
Why?
|
Adult | 58 | 2024 | 223088 | 0.230 |
Why?
|
Comorbidity | 17 | 2021 | 10575 | 0.230 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2024 | 25 | 0.230 |
Why?
|
Coronary Stenosis | 2 | 2020 | 798 | 0.230 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2017 | 1127 | 0.220 |
Why?
|
Heart Arrest | 6 | 2019 | 1516 | 0.220 |
Why?
|
Disease Progression | 17 | 2024 | 13614 | 0.220 |
Why?
|
Extracellular Matrix | 3 | 2020 | 1727 | 0.220 |
Why?
|
Dyspnea | 5 | 2023 | 1351 | 0.210 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2023 | 462 | 0.210 |
Why?
|
Registries | 10 | 2024 | 8346 | 0.210 |
Why?
|
Multiple Sclerosis | 1 | 2018 | 3212 | 0.210 |
Why?
|
Receptors, Angiotensin | 4 | 2024 | 141 | 0.210 |
Why?
|
Outpatients | 5 | 2024 | 1595 | 0.210 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2014 | 353 | 0.200 |
Why?
|
Protease Inhibitors | 2 | 2016 | 747 | 0.200 |
Why?
|
Electrocardiography | 6 | 2024 | 6409 | 0.200 |
Why?
|
Age Factors | 15 | 2024 | 18382 | 0.200 |
Why?
|
Fumarates | 2 | 2020 | 132 | 0.200 |
Why?
|
Brain Ischemia | 3 | 2023 | 3000 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2024 | 10727 | 0.200 |
Why?
|
Immunization Schedule | 2 | 2024 | 229 | 0.200 |
Why?
|
Hospital Mortality | 10 | 2024 | 5339 | 0.200 |
Why?
|
Myocardium | 5 | 2024 | 4764 | 0.190 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2018 | 562 | 0.190 |
Why?
|
Microscopy, Confocal | 4 | 2016 | 1966 | 0.190 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2024 | 198 | 0.190 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 3247 | 0.190 |
Why?
|
Amyloidosis, Familial | 1 | 2021 | 16 | 0.190 |
Why?
|
Ferritins | 3 | 2024 | 600 | 0.190 |
Why?
|
Antibody Formation | 2 | 2023 | 1392 | 0.180 |
Why?
|
Models, Statistical | 5 | 2020 | 5088 | 0.180 |
Why?
|
Seasons | 2 | 2024 | 1522 | 0.180 |
Why?
|
Macula Lutea | 1 | 2022 | 168 | 0.180 |
Why?
|
Creatinine | 7 | 2024 | 1916 | 0.180 |
Why?
|
Diabetes Complications | 3 | 2020 | 1318 | 0.180 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5189 | 0.180 |
Why?
|
Amides | 2 | 2020 | 451 | 0.180 |
Why?
|
Placebos | 3 | 2020 | 1659 | 0.170 |
Why?
|
Ventricular Pressure | 1 | 2021 | 210 | 0.170 |
Why?
|
North America | 6 | 2020 | 1287 | 0.170 |
Why?
|
Internationality | 5 | 2019 | 1007 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5752 | 0.170 |
Why?
|
Placebo Effect | 2 | 2015 | 515 | 0.170 |
Why?
|
Biological Factors | 1 | 2021 | 155 | 0.170 |
Why?
|
Body Mass Index | 9 | 2024 | 13042 | 0.170 |
Why?
|
Edema, Cardiac | 1 | 2019 | 19 | 0.170 |
Why?
|
Multicenter Studies as Topic | 3 | 2021 | 1729 | 0.170 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2019 | 68 | 0.170 |
Why?
|
Ultrasonography | 8 | 2021 | 5987 | 0.170 |
Why?
|
Metformin | 2 | 2019 | 904 | 0.170 |
Why?
|
Vital Capacity | 2 | 2022 | 995 | 0.160 |
Why?
|
Hemostasis, Endoscopic | 2 | 2017 | 42 | 0.160 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2024 | 363 | 0.160 |
Why?
|
Diuretics, Osmotic | 1 | 2019 | 32 | 0.160 |
Why?
|
Severity of Illness Index | 16 | 2021 | 15878 | 0.160 |
Why?
|
Hypercholesterolemia | 2 | 2018 | 1148 | 0.160 |
Why?
|
Drug Labeling | 1 | 2021 | 251 | 0.160 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 109 | 0.160 |
Why?
|
Hyperaldosteronism | 1 | 2022 | 252 | 0.160 |
Why?
|
Cardiac Myosins | 3 | 2024 | 128 | 0.160 |
Why?
|
Mannitol | 1 | 2019 | 176 | 0.150 |
Why?
|
Heart Diseases | 2 | 2022 | 2818 | 0.150 |
Why?
|
Sodium-Glucose Transporter 1 | 1 | 2018 | 108 | 0.150 |
Why?
|
Models, Cardiovascular | 1 | 2024 | 979 | 0.150 |
Why?
|
International Classification of Diseases | 2 | 2021 | 934 | 0.150 |
Why?
|
HIV Infections | 4 | 2024 | 17531 | 0.150 |
Why?
|
Atrial Appendage | 1 | 2022 | 284 | 0.150 |
Why?
|
C-Reactive Protein | 6 | 2024 | 3851 | 0.150 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2019 | 122 | 0.150 |
Why?
|
Hyperemia | 1 | 2019 | 223 | 0.150 |
Why?
|
Valine | 3 | 2014 | 410 | 0.150 |
Why?
|
Pneumonia | 3 | 2024 | 2158 | 0.150 |
Why?
|
Kidney Transplantation | 3 | 2018 | 4277 | 0.150 |
Why?
|
Uric Acid | 2 | 2023 | 809 | 0.150 |
Why?
|
Acute Disease | 7 | 2024 | 7236 | 0.150 |
Why?
|
Critical Care | 2 | 2021 | 2713 | 0.150 |
Why?
|
Patient Readmission | 3 | 2024 | 3282 | 0.150 |
Why?
|
Vasodilator Agents | 4 | 2023 | 988 | 0.140 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 530 | 0.140 |
Why?
|
Canrenone | 1 | 2017 | 5 | 0.140 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2018 | 207 | 0.140 |
Why?
|
Intestinal Absorption | 1 | 2018 | 400 | 0.140 |
Why?
|
Cardiac Volume | 1 | 2018 | 196 | 0.140 |
Why?
|
Virus Diseases | 1 | 2023 | 718 | 0.140 |
Why?
|
Apolipoprotein E4 | 1 | 2021 | 707 | 0.140 |
Why?
|
Retinal Vessels | 2 | 2022 | 847 | 0.140 |
Why?
|
Ileum | 3 | 2020 | 558 | 0.140 |
Why?
|
Adiposity | 2 | 2018 | 1891 | 0.140 |
Why?
|
Myocardial Contraction | 3 | 2024 | 1516 | 0.140 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2024 | 1093 | 0.140 |
Why?
|
Area Under Curve | 2 | 2018 | 1637 | 0.140 |
Why?
|
Estradiol | 1 | 2024 | 1947 | 0.140 |
Why?
|
Blood Urea Nitrogen | 1 | 2017 | 189 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2015 | 1898 | 0.140 |
Why?
|
Cross-Sectional Studies | 14 | 2024 | 26282 | 0.140 |
Why?
|
Hypoglycemia | 2 | 2022 | 896 | 0.140 |
Why?
|
Drug Therapy, Combination | 7 | 2024 | 6306 | 0.140 |
Why?
|
Digoxin | 2 | 2022 | 246 | 0.140 |
Why?
|
Pleural Effusion | 1 | 2020 | 344 | 0.130 |
Why?
|
Duodenal Diseases | 1 | 2017 | 101 | 0.130 |
Why?
|
beta Carotene | 1 | 2018 | 523 | 0.130 |
Why?
|
Retrospective Studies | 26 | 2023 | 81537 | 0.130 |
Why?
|
Multivariate Analysis | 10 | 2020 | 12059 | 0.130 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 156 | 0.130 |
Why?
|
Hyperglycemia | 3 | 2020 | 1389 | 0.130 |
Why?
|
Blood Pressure Determination | 1 | 2020 | 646 | 0.130 |
Why?
|
Hemoglobins | 2 | 2023 | 1531 | 0.130 |
Why?
|
Esophageal Diseases | 1 | 2017 | 167 | 0.130 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 551 | 0.130 |
Why?
|
Russia | 4 | 2018 | 383 | 0.130 |
Why?
|
Retinal Artery | 1 | 2016 | 108 | 0.130 |
Why?
|
Troponin | 1 | 2019 | 532 | 0.130 |
Why?
|
Gout | 1 | 2023 | 622 | 0.130 |
Why?
|
Health Status Disparities | 2 | 2018 | 1878 | 0.130 |
Why?
|
Young Adult | 18 | 2024 | 59857 | 0.130 |
Why?
|
Chronic Disease | 8 | 2024 | 9351 | 0.130 |
Why?
|
Stomach Diseases | 1 | 2017 | 134 | 0.130 |
Why?
|
Natural Language Processing | 1 | 2024 | 1198 | 0.120 |
Why?
|
Pandemics | 5 | 2023 | 8721 | 0.120 |
Why?
|
Vascular Resistance | 2 | 2015 | 939 | 0.120 |
Why?
|
Chi-Square Distribution | 6 | 2017 | 3430 | 0.120 |
Why?
|
Glucose Tolerance Test | 1 | 2018 | 1180 | 0.120 |
Why?
|
Therapeutics | 1 | 2015 | 113 | 0.120 |
Why?
|
Myocardial Ischemia | 2 | 2023 | 2132 | 0.120 |
Why?
|
Calcinosis | 1 | 2024 | 1475 | 0.120 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2015 | 109 | 0.120 |
Why?
|
Prehypertension | 1 | 2015 | 63 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2022 | 1029 | 0.120 |
Why?
|
Diabetic Neuropathies | 1 | 2018 | 407 | 0.120 |
Why?
|
Longevity | 2 | 2020 | 1088 | 0.120 |
Why?
|
Pulmonary Artery | 1 | 2023 | 1937 | 0.120 |
Why?
|
Prevalence | 11 | 2020 | 15828 | 0.120 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2020 | 669 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1394 | 0.120 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2015 | 61 | 0.120 |
Why?
|
Insulin | 3 | 2018 | 6603 | 0.120 |
Why?
|
Alcohol Drinking | 3 | 2019 | 4041 | 0.110 |
Why?
|
Captopril | 1 | 2015 | 261 | 0.110 |
Why?
|
Lung | 7 | 2023 | 10046 | 0.110 |
Why?
|
Aging | 3 | 2020 | 8725 | 0.110 |
Why?
|
Exercise | 4 | 2019 | 5936 | 0.110 |
Why?
|
Hypertension, Pulmonary | 2 | 2015 | 1604 | 0.110 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1257 | 0.110 |
Why?
|
Ventricular Fibrillation | 1 | 2017 | 538 | 0.110 |
Why?
|
Echocardiography, Three-Dimensional | 2 | 2018 | 611 | 0.110 |
Why?
|
Insulin Resistance | 2 | 2021 | 3988 | 0.110 |
Why?
|
Hemagglutination Inhibition Tests | 2 | 2024 | 87 | 0.110 |
Why?
|
Patient Dropouts | 1 | 2016 | 411 | 0.110 |
Why?
|
Delivery, Obstetric | 1 | 2021 | 947 | 0.110 |
Why?
|
Aortic Valve | 1 | 2024 | 1964 | 0.110 |
Why?
|
Tissue Survival | 1 | 2014 | 120 | 0.110 |
Why?
|
Endoscopy, Digestive System | 1 | 2016 | 358 | 0.110 |
Why?
|
Geriatric Assessment | 2 | 2019 | 1422 | 0.110 |
Why?
|
Hemodynamics | 4 | 2021 | 4186 | 0.110 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 164 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2022 | 1161 | 0.110 |
Why?
|
Electric Countershock | 1 | 2017 | 536 | 0.110 |
Why?
|
Dietary Carbohydrates | 1 | 2018 | 896 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2125 | 0.110 |
Why?
|
Forced Expiratory Volume | 1 | 2018 | 1828 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1673 | 0.110 |
Why?
|
Coronary Artery Bypass | 1 | 2022 | 2188 | 0.110 |
Why?
|
Cost of Illness | 2 | 2024 | 1949 | 0.100 |
Why?
|
Algorithms | 4 | 2024 | 14064 | 0.100 |
Why?
|
Gastric Mucosa | 1 | 2016 | 602 | 0.100 |
Why?
|
Frail Elderly | 1 | 2018 | 782 | 0.100 |
Why?
|
Patients | 2 | 2021 | 908 | 0.100 |
Why?
|
Georgia (Republic) | 3 | 2018 | 39 | 0.100 |
Why?
|
Malnutrition | 1 | 2019 | 629 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3109 | 0.100 |
Why?
|
Colitis, Ulcerative | 2 | 2017 | 1912 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3231 | 0.100 |
Why?
|
Government | 2 | 2023 | 161 | 0.100 |
Why?
|
Aftercare | 3 | 2023 | 915 | 0.100 |
Why?
|
Argentina | 3 | 2018 | 249 | 0.100 |
Why?
|
Colonoscopy | 2 | 2020 | 1408 | 0.100 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.100 |
Why?
|
Influenza A virus | 1 | 2015 | 453 | 0.100 |
Why?
|
Case-Control Studies | 9 | 2024 | 22228 | 0.100 |
Why?
|
Colchicine | 2 | 2023 | 256 | 0.100 |
Why?
|
Oxygen Consumption | 3 | 2024 | 1872 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2021 | 1366 | 0.100 |
Why?
|
Nervous System | 1 | 2015 | 542 | 0.100 |
Why?
|
Peripheral Arterial Disease | 1 | 2023 | 1308 | 0.100 |
Why?
|
Computer Simulation | 4 | 2018 | 6251 | 0.090 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 691 | 0.090 |
Why?
|
Adolescent | 14 | 2024 | 88811 | 0.090 |
Why?
|
Canada | 4 | 2018 | 2120 | 0.090 |
Why?
|
Sweden | 3 | 2020 | 1381 | 0.090 |
Why?
|
Social Behavior | 1 | 2018 | 1143 | 0.090 |
Why?
|
Malaria | 1 | 2021 | 1246 | 0.090 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3213 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2022 | 0.090 |
Why?
|
Radiotherapy | 1 | 2018 | 1491 | 0.090 |
Why?
|
Organ Transplantation | 1 | 2021 | 1172 | 0.090 |
Why?
|
Coronary Angiography | 2 | 2020 | 4498 | 0.090 |
Why?
|
Vaccines, Inactivated | 2 | 2023 | 186 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1883 | 0.090 |
Why?
|
Los Angeles | 2 | 2022 | 244 | 0.090 |
Why?
|
Income | 1 | 2019 | 1874 | 0.090 |
Why?
|
Heart Transplantation | 2 | 2022 | 3310 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1881 | 0.090 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2017 | 889 | 0.090 |
Why?
|
New York | 2 | 2023 | 880 | 0.090 |
Why?
|
Pulmonary Circulation | 2 | 2024 | 744 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 3 | 2015 | 5691 | 0.090 |
Why?
|
Health Status Indicators | 1 | 2015 | 967 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1600 | 0.080 |
Why?
|
Renal Insufficiency | 1 | 2016 | 810 | 0.080 |
Why?
|
Cardiology | 1 | 2021 | 1696 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3419 | 0.080 |
Why?
|
Cognition | 2 | 2024 | 7043 | 0.080 |
Why?
|
Single-Blind Method | 3 | 2019 | 1587 | 0.080 |
Why?
|
Thromboembolism | 1 | 2016 | 1001 | 0.080 |
Why?
|
Drug Monitoring | 3 | 2020 | 960 | 0.080 |
Why?
|
Patient Compliance | 1 | 2020 | 2693 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1939 | 0.080 |
Why?
|
Procollagen | 2 | 2023 | 189 | 0.080 |
Why?
|
Patient Selection | 3 | 2017 | 4248 | 0.080 |
Why?
|
Diabetic Retinopathy | 1 | 2018 | 1294 | 0.080 |
Why?
|
Up-Regulation | 4 | 2021 | 4130 | 0.080 |
Why?
|
Extracellular Space | 1 | 2011 | 563 | 0.080 |
Why?
|
Breast Feeding | 1 | 2017 | 1363 | 0.080 |
Why?
|
Acupuncture Therapy | 1 | 2013 | 466 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2184 | 0.080 |
Why?
|
Morbidity | 3 | 2020 | 1752 | 0.080 |
Why?
|
Forecasting | 1 | 2018 | 2936 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1376 | 0.080 |
Why?
|
Brazil | 3 | 2018 | 1248 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2004 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1143 | 0.080 |
Why?
|
Epithelial Cells | 2 | 2021 | 3684 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 3078 | 0.070 |
Why?
|
Patient Discharge | 4 | 2023 | 3460 | 0.070 |
Why?
|
Risk | 5 | 2018 | 9599 | 0.070 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2012 | 772 | 0.070 |
Why?
|
Triglycerides | 3 | 2021 | 2440 | 0.070 |
Why?
|
Metabolomics | 1 | 2017 | 1667 | 0.070 |
Why?
|
Irritable Bowel Syndrome | 1 | 2013 | 454 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2017 | 3360 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2596 | 0.070 |
Why?
|
Sodium | 2 | 2022 | 1591 | 0.070 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2023 | 373 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2018 | 3444 | 0.070 |
Why?
|
Aspirin | 1 | 2018 | 3135 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2020 | 2787 | 0.070 |
Why?
|
Odds Ratio | 4 | 2019 | 9656 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5784 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 2 | 2013 | 2255 | 0.060 |
Why?
|
Body Weight | 1 | 2016 | 4627 | 0.060 |
Why?
|
Linear Models | 4 | 2017 | 5873 | 0.060 |
Why?
|
Glucose | 3 | 2022 | 4335 | 0.060 |
Why?
|
Medication Adherence | 1 | 2017 | 2190 | 0.060 |
Why?
|
Reproducibility of Results | 5 | 2023 | 20133 | 0.060 |
Why?
|
Japan | 2 | 2020 | 1411 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3249 | 0.060 |
Why?
|
Depression | 2 | 2021 | 8223 | 0.060 |
Why?
|
Blood Proteins | 2 | 2023 | 1186 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5509 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2016 | 2430 | 0.060 |
Why?
|
Cost-Benefit Analysis | 3 | 2024 | 5531 | 0.060 |
Why?
|
Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
Administration, Intravaginal | 1 | 2024 | 149 | 0.060 |
Why?
|
Matrix Metalloproteinase 12 | 1 | 2024 | 45 | 0.060 |
Why?
|
Kidney Function Tests | 2 | 2017 | 684 | 0.060 |
Why?
|
Valsalva Maneuver | 1 | 2024 | 99 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2024 | 1786 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2546 | 0.060 |
Why?
|
Kansas | 1 | 2023 | 37 | 0.050 |
Why?
|
American Heart Association | 2 | 2021 | 1045 | 0.050 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2024 | 355 | 0.050 |
Why?
|
Europe, Eastern | 1 | 2023 | 72 | 0.050 |
Why?
|
Heterozygote | 2 | 2024 | 2796 | 0.050 |
Why?
|
Adrenomedullin | 1 | 2023 | 85 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2017 | 15802 | 0.050 |
Why?
|
Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
Physical Examination | 2 | 2019 | 1263 | 0.050 |
Why?
|
Aptamers, Nucleotide | 1 | 2024 | 163 | 0.050 |
Why?
|
Colon | 1 | 2011 | 1796 | 0.050 |
Why?
|
Mineralocorticoids | 1 | 2022 | 37 | 0.050 |
Why?
|
Renin-Angiotensin System | 2 | 2018 | 736 | 0.050 |
Why?
|
Fibrosis | 2 | 2023 | 2073 | 0.050 |
Why?
|
Organ Size | 2 | 2020 | 2261 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11030 | 0.050 |
Why?
|
Barbiturates | 1 | 2022 | 113 | 0.050 |
Why?
|
Carbamates | 1 | 2024 | 191 | 0.050 |
Why?
|
Pyrimidines | 1 | 2014 | 3049 | 0.050 |
Why?
|
Cholesterol | 2 | 2021 | 2902 | 0.050 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2024 | 262 | 0.050 |
Why?
|
Pain | 2 | 2015 | 5077 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2023 | 2414 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 16039 | 0.050 |
Why?
|
Electronics | 1 | 2023 | 314 | 0.050 |
Why?
|
Stress, Mechanical | 2 | 2017 | 1670 | 0.050 |
Why?
|
Child | 7 | 2024 | 80568 | 0.050 |
Why?
|
Psychomotor Agitation | 1 | 2023 | 307 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2023 | 5300 | 0.040 |
Why?
|
Oligonucleotides | 1 | 2023 | 561 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4555 | 0.040 |
Why?
|
ROC Curve | 2 | 2019 | 3612 | 0.040 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 150 | 0.040 |
Why?
|
Glycine | 1 | 2024 | 671 | 0.040 |
Why?
|
Amyloidogenic Proteins | 1 | 2021 | 152 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2021 | 8722 | 0.040 |
Why?
|
Atrial Flutter | 1 | 2022 | 253 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2023 | 3716 | 0.040 |
Why?
|
Renin | 1 | 2022 | 647 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 1 | 2024 | 833 | 0.040 |
Why?
|
Erythropoiesis | 1 | 2023 | 691 | 0.040 |
Why?
|
Hypertonic Solutions | 1 | 2019 | 82 | 0.040 |
Why?
|
Causality | 2 | 2016 | 1247 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1132 | 0.040 |
Why?
|
Nebulizers and Vaporizers | 1 | 2019 | 138 | 0.040 |
Why?
|
Quebec | 1 | 2018 | 140 | 0.040 |
Why?
|
Americas | 1 | 2018 | 110 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2653 | 0.040 |
Why?
|
Microcirculation | 1 | 2023 | 1282 | 0.040 |
Why?
|
Biological Availability | 1 | 2019 | 387 | 0.040 |
Why?
|
Regression Analysis | 2 | 2018 | 6321 | 0.040 |
Why?
|
Tomography | 1 | 2020 | 443 | 0.040 |
Why?
|
Lipoproteins, LDL | 1 | 2021 | 643 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1527 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.040 |
Why?
|
Polyneuropathies | 1 | 2019 | 139 | 0.040 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2023 | 1164 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Precipitating Factors | 1 | 2017 | 51 | 0.040 |
Why?
|
Hot Temperature | 2 | 2015 | 1433 | 0.040 |
Why?
|
Polysomnography | 2 | 2015 | 1868 | 0.040 |
Why?
|
South Africa | 1 | 2023 | 1868 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2530 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1640 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2022 | 968 | 0.030 |
Why?
|
Residence Characteristics | 2 | 2019 | 2116 | 0.030 |
Why?
|
Aldosterone | 1 | 2022 | 881 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2024 | 1353 | 0.030 |
Why?
|
Fluorescein Angiography | 1 | 2022 | 1047 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2021 | 676 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2019 | 1154 | 0.030 |
Why?
|
Ontario | 1 | 2017 | 402 | 0.030 |
Why?
|
Myocarditis | 1 | 2024 | 803 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2021 | 570 | 0.030 |
Why?
|
Photography | 1 | 2019 | 535 | 0.030 |
Why?
|
Glycoproteins | 1 | 2024 | 2196 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4016 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2019 | 513 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2019 | 738 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2021 | 1459 | 0.030 |
Why?
|
Protein Precursors | 1 | 2020 | 1133 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2277 | 0.030 |
Why?
|
Genetic Variation | 2 | 2023 | 6612 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1735 | 0.030 |
Why?
|
Pulmonary Ventilation | 1 | 2017 | 375 | 0.030 |
Why?
|
Death | 1 | 2020 | 686 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 598 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1084 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13631 | 0.030 |
Why?
|
Spirometry | 1 | 2018 | 929 | 0.030 |
Why?
|
Self Efficacy | 1 | 2019 | 641 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2018 | 539 | 0.030 |
Why?
|
Death Certificates | 1 | 2015 | 172 | 0.030 |
Why?
|
South America | 1 | 2014 | 180 | 0.030 |
Why?
|
Periaqueductal Gray | 1 | 2015 | 111 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42510 | 0.030 |
Why?
|
Diet Surveys | 1 | 2018 | 1159 | 0.030 |
Why?
|
Leisure Activities | 1 | 2016 | 310 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1787 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2227 | 0.030 |
Why?
|
Pilot Projects | 2 | 2019 | 8724 | 0.030 |
Why?
|
Stochastic Processes | 1 | 2015 | 358 | 0.030 |
Why?
|
Capsaicin | 1 | 2015 | 226 | 0.030 |
Why?
|
Galectin 3 | 1 | 2016 | 238 | 0.030 |
Why?
|
HIV-1 | 2 | 2024 | 6945 | 0.030 |
Why?
|
Fibrinolytic Agents | 1 | 2023 | 2076 | 0.030 |
Why?
|
Plasma | 1 | 2017 | 583 | 0.030 |
Why?
|
Drug Substitution | 1 | 2016 | 292 | 0.030 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2014 | 185 | 0.030 |
Why?
|
Pain Perception | 1 | 2015 | 198 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14643 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2017 | 1138 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2017 | 1527 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13446 | 0.030 |
Why?
|
Acupuncture Points | 1 | 2013 | 97 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18074 | 0.030 |
Why?
|
Caspases | 1 | 2016 | 880 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2353 | 0.030 |
Why?
|
Galectins | 1 | 2016 | 293 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2018 | 1038 | 0.030 |
Why?
|
Inflammation | 2 | 2024 | 10843 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16714 | 0.030 |
Why?
|
Radiology, Interventional | 1 | 2017 | 484 | 0.030 |
Why?
|
Waist Circumference | 1 | 2016 | 934 | 0.030 |
Why?
|
Independent Living | 1 | 2016 | 583 | 0.030 |
Why?
|
Cardiovascular System | 1 | 2020 | 838 | 0.020 |
Why?
|
Australia | 1 | 2016 | 1260 | 0.020 |
Why?
|
Drug Resistance | 1 | 2018 | 1588 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2016 | 1072 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2018 | 2586 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1971 | 0.020 |
Why?
|
Lidocaine | 1 | 2015 | 545 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2515 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2022 | 2782 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13273 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2018 | 2350 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2563 | 0.020 |
Why?
|
Angina, Unstable | 1 | 2015 | 893 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3801 | 0.020 |
Why?
|
Action Potentials | 1 | 2019 | 1837 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3343 | 0.020 |
Why?
|
Neutrophils | 1 | 2023 | 3769 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2024 | 4909 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2339 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 586 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2017 | 1194 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 30230 | 0.020 |
Why?
|
Reference Values | 1 | 2017 | 4909 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2969 | 0.020 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2013 | 369 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 996 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2661 | 0.020 |
Why?
|
Benzazepines | 1 | 2012 | 308 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2717 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2269 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2018 | 1899 | 0.020 |
Why?
|
Pain Threshold | 1 | 2013 | 603 | 0.020 |
Why?
|
Acetaminophen | 1 | 2013 | 549 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2022 | 2876 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3385 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6766 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1813 | 0.020 |
Why?
|
Health Personnel | 1 | 2022 | 3385 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 4249 | 0.020 |
Why?
|
Cues | 1 | 2013 | 876 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2024 | 4558 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2019 | 1945 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2015 | 1404 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2270 | 0.020 |
Why?
|
Iron | 1 | 2016 | 1811 | 0.020 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 872 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2015 | 1004 | 0.020 |
Why?
|
Reward | 1 | 2015 | 980 | 0.020 |
Why?
|
Genetic Testing | 1 | 2021 | 3594 | 0.020 |
Why?
|
Tachycardia, Ventricular | 1 | 2017 | 1313 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3886 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4851 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2520 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2019 | 4423 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2680 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2108 | 0.020 |
Why?
|
Cell Count | 1 | 2011 | 1823 | 0.020 |
Why?
|
Lipids | 1 | 2018 | 3317 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2016 | 2814 | 0.020 |
Why?
|
Epithelium | 1 | 2011 | 1603 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2019 | 3799 | 0.020 |
Why?
|
Length of Stay | 1 | 2019 | 6486 | 0.020 |
Why?
|
Medicare | 1 | 2024 | 6815 | 0.020 |
Why?
|
Recovery of Function | 1 | 2016 | 2963 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 2395 | 0.020 |
Why?
|
Motor Activity | 1 | 2015 | 2705 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2844 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8882 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6202 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4213 | 0.010 |
Why?
|
Liver | 1 | 2020 | 7559 | 0.010 |
Why?
|
Overweight | 1 | 2015 | 2444 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3558 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36547 | 0.010 |
Why?
|
Anticoagulants | 1 | 2016 | 4856 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 13026 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7423 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5765 | 0.010 |
Why?
|
Infant | 1 | 2020 | 36426 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7871 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30192 | 0.010 |
Why?
|